Delving into the Latest Updates on Fermagate with Synapse

Overview

Basic Info

Drug Type

Small molecule drug

Synonyms

Alpharen, Macrosorb MD

Target

Phosphates

Action

modulators

Mechanism

Phosphates modulators(Phosphates modulators)

Therapeutic Areas

Endocrinology and Metabolic Disease

Active Indication

HyperphosphatemiaHypophosphatemia

Inactive Indication

Kidney Failure, Chronic

Originator Organization

Ineos Healthcare Ltd.

Active Organization

Prolor Biotech Ltd.Ineos Healthcare Ltd.

Inactive Organization

OPKO Renal LLC

License Organization-

Drug Highest PhasePhase 3

First Approval Date-

Regulation-

Login to view timeline

Structure/Sequence

Molecular FormulaCH20Fe2Mg4O19

InChIKeyVESOWWBEYMMDFG-UHFFFAOYSA-A

CAS Registry119175-48-3

Magnesium iron hydroxycarbonate is a phosphate binder that absorbs phosphate from food, reducing the amount that the body can absorb.
The purpose of this study is to assess the efficacy of magnesium iron hydroxycarbonate in subjects requiring haemodialysis, compared with a marketed phosphate binder, sevelamer hydrochloride.

Start Date01 Jul 2009

Sponsor / Collaborator

Ineos Healthcare Ltd.

NCT00436683

/ CompletedPhase 2

An Open Label, Dose-Ranging Study to Establish the Tolerability of Magnesium Iron Hydroxycarbonate in Haemodialysis Subjects With Hyperphosphataemia.

Magnesium iron hydroxycarbonate is a phosphate binder that absorbs phosphate from food, reducing the amount that the body can absorb.
The purpose of this study is to determine how well a range of different doses of fermagate are tolerated by the subjects in the trial.

Start Date01 Feb 2007

Sponsor / Collaborator

Ineos Healthcare Ltd.

NCT00358722

/ TerminatedPhase 2

A Long-term, Open-label Continuation Study to Assess the Safety of Magnesium Iron Hydroxycarbonate in Haemodialysis Subjects With Hyperphosphataemia

Fermagate is a phosphate binder that absorbs phosphate from food, reducing the amount that the body can absorb.
The purpose of this study it to look at the safety of fermagate over longer periods of time.

Start Date01 Jul 2006

Sponsor / Collaborator

Ineos Healthcare Ltd.

100 Clinical Results associated with Fermagate

Login to view more data

100 Translational Medicine associated with Fermagate

Login to view more data

100 Patents (Medical) associated with Fermagate

Login to view more data

3

Literatures (Medical) associated with Fermagate

01 Sep 2021·International urology and nephrologyQ4 · MEDICINE

Using iron-based phosphate binders in phosphate reduction and anemia improvement in patients receiving dialysis: a meta-analysis of randomized controlled trials

Q4 · MEDICINE

Article

Author: Zhu, Yan ; Li, Wei ; Xue, Chao ; Liao, Xueling ; Rao, Jinlan ; Ou, Jihong

PURPOSE:

A study was conducted to determine whether iron-based phosphate binders (IBPBs) need to be preferred for hyperphosphatemia and anemia management in patients on dialysis.

METHODS:

For this meta-analysis, we searched PubMed, Embase, and Cochrane Central Register of Controlled Trials for randomized controlled trials that evaluated the efficacy and safety of IBPBs in decreasing phosphate and correcting anemia in dialysis patients.

RESULTS:

Nineteen trials comprising 4719 participants were included. Compared with placebo, serum phosphate decreased significantly after treatment with ferric citrate (FC), fermagate (one study), and SBR759 (one study). Hemoglobin increased significantly after treatment with FC and sucroferric oxyhydroxide (PA21). In addition, FC and PA21 reduced serum intact parathyroid hormone (iPTH) and increased ferritin and transferrin saturation, but SBR759 did not. Compared with active treatment, the non-inferiority of IBPBs in reducing serum phosphate and iPTH was demonstrated. FC significantly improved serum hemoglobin and iron-related parameters and decreased the use of intravenous iron and erythropoiesis-stimulating agent, whereas PA21 did not increase serum hemoglobin level. The incidences of infection and hospitalization were similar between the two groups, with FC having a higher risk of diarrhea than the placebo and active treatments.

CONCLUSION:

FC was associated with the control of hyperphosphatemia and the improvement of anemia. However, PA21 did not show superiority for alleviating anemia compared with the active treatment. Other IBPBs, such as fermagate and SBR759, remained poorly understood due to the limited number of studies. Further trials are required to assess the effect of IBPBs on the risk of cardiovascular events and all-cause mortality.

02 Jan 2015·Renal failureQ4 · MEDICINE

Effects and safety of iron-based phosphate binders in dialysis patients: a systematic review and meta-analysis

Q4 · MEDICINE

ReviewOA

Author: Sun, Jing ; Zhai, Chun-Juan ; Wang, Rong ; Yu, Xin-Shuang ; Yang, Xiao-Wei

AIM:

To assess the effects and safety of iron-based phosphate binders in adult patients receiving dialysis.

METHODS:

We electronically searched MEDLINE, EMBASE, CENTRAL, and CBM for randomized controlled trials about iron-based phosphate binders in adult dialysis patients. Study quality was assessed using the criteria outlined in the Cochrane Handbook for Systematic Reviews of intervention. Meta-analysis was conducted by RevMan 5.3.

RESULTS:

Eight studies with 2018 participants were eligible for our meta-analysis. Iron-based phosphate binders were superior to placebo (MD = -2.43 mg/dL, 95% CI: -3.18 to -1.68, p < 0.00001) and as efficient as sevelamer (MD = 0.04 mg/dL, 95% CI: -0.29 to 0.36, p = 0.83) in reducing serum phosphorus in dialysis patients. No significant differences were found in all adverse events (OR = 1.30, 95% CI: 0.77 to 2.20, p = 0.32) between iron-based phosphate binders and placebo. Iron-based phosphate binders were associated with significant higher serum iron (MD = 9.39 ng/mL, 95% CI 1.48 to 17.30, p = 0.02), higher serum transferring saturation (MD = 6.29%, 95% CI 2.72 to 9.87, p = 0.0006) and lower serum total iron binding capacity (MD = -23.13 µg/dL, 95% CI -35.69 to -10.58, p = 0.0003) in comparison to placebo.

CONCLUSION:

Iron-based phosphate binders are as effective as sevelamer and well tolerated for hyperphosphatemia in dialysis patients. Iron-based phosphate binders appear to have a beneficial effect on renal anemia in patients receiving dialysis. Therefore, iron-based phosphate binders may represent a new treatment option for dialysis patients.

01 Oct 1988·THERMOCHIMICA ACTA

Kinetics of the thermal dehydration of some layered hydroxycarbonates

Author: Ulibarri, M. A. ; Cornejo, J. ; Barriga, C.

The kinetics of thermal dehydration of hydrotalcite, Mg₆Al₂(OH)₁₆CO₃.4H₂O, and other related hydroxycarbonates were studied by anal. of both dynamic and isothermal weight loss data.The results indicate that the H₂O loss occurs through a diffusion mechanism, in accord with the layered structure of the compounds

100 Deals associated with Fermagate

Login to view more data

External Link

KEGG	Wiki	ATC	Drug Bank
-	Fermagate	-	-

R&D Status

10 top R&D records.

Login

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Kidney Failure, Chronic	Phase 3	United States	Ineos Healthcare Ltd.	01 Jul 2009
Kidney Failure, Chronic	Phase 3	Belgium	Ineos Healthcare Ltd.	01 Jul 2009
Kidney Failure, Chronic	Phase 3	Brazil	Ineos Healthcare Ltd.	01 Jul 2009
Kidney Failure, Chronic	Phase 3	Bulgaria	Ineos Healthcare Ltd.	01 Jul 2009
Kidney Failure, Chronic	Phase 3	Czechia	Ineos Healthcare Ltd.	01 Jul 2009
Kidney Failure, Chronic	Phase 3	Estonia	Ineos Healthcare Ltd.	01 Jul 2009
Kidney Failure, Chronic	Phase 3	Hungary	Ineos Healthcare Ltd.	01 Jul 2009
Kidney Failure, Chronic	Phase 3	Israel	Ineos Healthcare Ltd.	01 Jul 2009
Kidney Failure, Chronic	Phase 3	Italy	Ineos Healthcare Ltd.	01 Jul 2009
Kidney Failure, Chronic	Phase 3	Lithuania	Ineos Healthcare Ltd.	01 Jul 2009

Login to view more data

Clinical Result

Indication

Phase

Evaluation

View All Results

Study	Phase	Population	Analyzed Enrollment	Group	Results	Evaluation	Publication Date


phase 3 study (ASN2012)	Phase 3	-	-	Fermagate 1.5 g/d	yydabdmouk(dxelakcjdh) = 11.6% for F aunghcgoxm (ekbzmjfmbi ) View more	Positive	30 Oct 2012
				Sevelamer HCl 2.4 g/d